WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 14, Issue 21, 296-313. Review Article ISSN 2277–7105

INSOMNIA (SLEEPLESSNESS) INCLUDES BOTH PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT APPROACHES & THE CURRENT STATUS OF EPIDEMIOLOGY

Yash Srivastav[1]*, Nutan Shrivastava[2], Madhaw Kumar[3], Nikita Sharma[4]

[1]*Shri Venkateshwara University, Gajraula, Uttar Pradesh, India.

[2]City Women's College, Jankipuram, Lucknow, Uttar Pradesh, India.

[3]Goel Institute of Pharmacy and Sciences, Lucknow, Uttar Pradesh, India.

[4]Signa College of Pharmacy, Kanpur, Uttar Pradesh, India.

Article Received on 27 Sept. 2025,
Article Revised on 17 October 2025,
Article Published on 01 Nov. 2025,

https://doi.org/10.5281/zenodo.17472944

***Corresponding Author**

Yash Srivastav

Shri Venkateshwara University, Gajraula, Uttar Pradesh, India.

How to cite this Article: Yash Srivastav, Nutan Shrivastava, Madhaw Kumar, Nikita Sharma. (2025). Insomnia (Sleeplessness) Includes Both Pharmacological And Non-Pharmacological Treatment Approaches & The Current Status Of Epidemiology . World Journal of Pharmaceutical Research, 14(21), 296–313.

ABSTRACT

The definitions of "insomnia" and "severe insomnia" were taken from the best-quality reference study available for countries without a country-specific estimate of the prevalence of insomnia. The Online Etymology Dictionary states that the word "insomnia" first appeared in 1623 and was Anglicised as "insomnie." It comes from the Latin insomnia, which means "want of sleep," and is made up of the words "in," which means not, and "somnus," which means sleep. The current version was first used in 1758. In that study, insomnia was classified as either severe (supporting two or more DSM-IV insomnia symptoms with daytime consequences) or chronic (supporting one DSM-IV sleep-related insomnia symptom with daytime consequences). The term "insomnia" was coined during the Enlightenment period of thriving new sciences in the late 18th century, and where there is "insomnia," there must be "insomniacs." As a result, the word "insomniacs" was coined to describe those who had trouble sleeping. This was given its current meaning at the beginning of the 20th century. Among those who acknowledged having trouble sleeping are Winston Churchill, Charles Dickens, Isaac Newton, and Benjamin Franklin. Although they didn't use the term "insomnia," you get the idea. A well-documented historical concern is insomnia. It includes

worry and distress during the day, as well as trouble falling or staying asleep. The causes of sleeplessness are numerous and diverse. These include physical or mental health conditions, medications, how and where we live and work, and biological changes brought on by ageing or hormones. As a result, the word "insomniacs" was coined to describe those who had trouble sleeping. Medical treatments for insomnia started to proliferate, and some of them were presumably successful. For instance, Grimault & Co.'s "Indian Cigarettes" were promoted in Australia throughout the 1800s. They had cannabis in them. According to recent figures, 10–30% of individuals worldwide suffer from sleeplessness. Up to 237,000,000 individuals are impacted, depending on the present population of the world. For these sleep issues to be diagnosed as insomnia, they must also result in daytime impairments like drowsiness or trouble focusing. Symptoms of insomnia can occasionally affect up to two-thirds of the population. Using a variety of techniques, including questioning you about your medical history, current situation, sleep patterns, symptoms, and more, a healthcare professional can diagnose insomnia. In order to rule out additional illnesses that might contribute to or cause insomnia, they might also suggest certain tests. Belsomra, Ambien, Dayvigo, Quviviq, Lunesta, Restoril, and numerous other medications are used to treat insomnia. There are over-the-counter (OTC) and prescription sleep aids for insomnia, such as ZzzQuil and Unisom. This review article discusses the pathophysiology, aetiology, diagnosis, therapy, and hazards of insomnia.

KEYWORDS: Insomnia, Epidemiology, Aetiology, Treatments.

INTRODUCTION

One of the most prevalent sleep disorders in adults worldwide is insomnia disorder, which is characterised by frequent and ongoing trouble falling asleep and/or staying asleep, with related daily repercussions. Insomnia was formerly thought to be a subsequent disease to mental and medical disorders, but it is now generally acknowledged that it is a separate illness that requires diagnosis and treatment.[1] A common sleep issue that is either misdiagnosed or not adequately treated is insomnia. Subjective trouble falling or staying asleep is its clinical hallmark, and in order to meet the ICSD-3 diagnostic criteria, it must be present for at least three days per week for three months. Crucially, insomnia still happens even when there are enough possibilities for sleep, and it manifests as symptoms during the day. The DSM-5 and ICD-10 have created and suggested similar criteria. Adults may have daytime side effects such as memory loss, exhaustion, difficulty concentrating, decreased

motivation, and irritability. People who are impacted may express uneasiness or discontent with the quality of their sleep.[2-4] Parents or other caregivers often report poor academic performance and resistance to going to bed in children with insomnia. The prevalence of insomnia in the adult population is estimated to range from 10% to 40%. This ambiguity results from ignorance of the intricate diagnostic standards needed to reach a conclusive diagnosis. Spielman's three-factor model, which divides contributing reasons for insomnia into predisposing, triggering, and perpetuating components, defines these elements. A positive family history of insomnia, advanced age, female gender, depression, elevated perceived stress, hypnotic usage, and substance misuse, and depression are all risk factors. Insomnia has been linked to lower socioeconomic position, but racial and ethnic minorities are less likely to report it, maybe due to concerns about potential job consequences. Numerous long-term illnesses, such as cancer, heart disease, neurological disorders, persistent gastrointestinal and urinary problems, and chronic pain, have been connected to insomnia.[5] People of all ages are affected by chronic insomnia, which is characterised as difficulty falling or staying asleep at least three nights per week for three months or more. Women are more likely to experience this condition than men. In adults, chronic insomnia is linked to numerous physical and mental comorbidities, excessive daytime sleepiness, and an increased risk of car accidents. It may also impede the growth of children. The most common sleep condition, chronic insomnia, is a common worry when seeing a primary care physician. The International Classification of Sleep Disorders, Third Edition (ICSD-3) of the American Academy of Sleep Medicine states that difficulties falling asleep, staying asleep, or having poor quality sleep are the hallmarks of persistent insomnia. Despite having enough opportunities for sleep, these symptoms have persisted for more than three months, occurring three nights a week or more, leading to dysfunction during the day. Self-reported symptoms are the primary basis for diagnosing persistent insomnia.[6,7] Persistent insomnia can hurt one's health, quality of life, and scholastic achievement. It can also raise the risk of car accidents, reduce productivity at work, aggravate irritability, and increase daytime sleepiness. Depression, anxiety, PTSD, hypertension, chronic pain, gastroesophageal reflux disease, chronic obstructive pulmonary disease, asthma, benign prostatic hyperplasia, obstructive sleep apnea, vasomotor symptoms, and substance use disorders are among the many comorbidities linked to chronic insomnia. Numerous detrimental medical (such as cardiovascular, metabolic, and neurodegenerative disorders) and mental health (such as depression, anxiety, chronic pain, and substance abuse) effects, as well as a lower quality of life, are linked to insomnia. Furthermore, insomnia is linked to a sharp rise in the financial

expenditures faced by a number of parties, including employers (due to decreased working productivity and an elevated risk of accidents), payers (increasing costs and healthcare resource consumption), and society at large.[8] Determining a condition's population prevalence is a necessary step in comprehending disease burden. However, little is known about the true number of people with insomnia from a global health viewpoint, although the condition is widely acknowledged to be a burden and evidence-based therapies are available. This study conducted a systematic literature analysis and then quantitatively synthesised the existing data to estimate the prevalence of adult insomnia worldwide in order to fill in these significant knowledge gaps. We used four criteria to decide which estimates of the prevalence of insomnia to apply to UN population data: 1) stratified results were used for studies that reported age and sex combined (i.e., prevalence of insomnia in males and females, separately, by age); 2) Age-based results were used for studies that reported the prevalence of insomnia by age and sex separately (because age allowed for a more detailed breakdown than sex); 3) sex-based results were used for studies that reported the prevalence of insomnia by sex but not by age; 4) studies that reported only one prevalence estimate applied that estimate to the entire population of that nation. Expert judgment was utilised to choose the most methodologically rigorous study based on the previously mentioned criteria for nations with more than one possible reference study, age and sex categories in biology.[9-12]

Fig. 1: Suffering from Sleeplessness (Insomnia).

CATEGORIZATION OF INSOMNIA

The length of symptoms determines the classification of insomnia. Symptoms of chronic insomnia must manifest at least three times each week for a minimum of three months.

Symptoms of short-term insomnia typically resolve within three months. It frequently occurs in response to acute stresses and goes away when the stressor is resolved, but in the presence of perpetuating factors, it can develop into chronic insomnia.[13]



Fig. 2: Lack of sleep, the physiological model.

EPIDEMIOLOGY

There are estimates that the prevalence of insomnia in adults ranges from 10% to 40%. This ambiguity results from ignorance and the difficulty of the diagnostic standards needed to reach a firm diagnosis. Using Spielman's three-factor model, contributing reasons for insomnia are categorised as predisposing, precipitating, and perpetuating factors. Psychiatric conditions such as anxiety, sadness, and post-traumatic stress disorder are identified in up to 40% of those impacted.

Stressful life events, physical or mental health conditions, and drugs like steroids that can induce sleeplessness are examples of precipitating factors. Maladaptive reactions like midday naps and rising anxiety are examples of perpetuating factors that keep this process going and ultimately lead to chronic insomnia.[14-18] In addition to its health repercussions, insomnia affects society economically. Chronic absenteeism and a tendency to self-medicate with alcohol and over-the-counter drugs are two consequences of insomnia. When direct healthcare costs are taken out of the equation, the projected annual indirect cost to the economy is above $60 billion. Timely diagnosis and the implementation of suitable therapeutic procedures can significantly reduce these expenses. In general, between 30% and 36% of adults report having at least one insomnia symptom. Prevalence rates range from 6% to 10% when using the rigorous diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (ICSD-3). Middle-aged and older people, shift workers, women, and patients with co-occurring mental and medical conditions are more

likely to experience insomnia. Insomnia prevalence varies greatly across the globe, from 23.2% in Western Europe to 79% in Brazil. RLS was 10.6%, OSA was 37.4%, and the combined frequency of insomnia was 25.7%. Patients with diabetes, heart disease patients, and the general population showed a higher prevalence.[19] A questionnaire-based assessment conducted in Mumbai revealed that 7.5% of people had sleep disorders. The prevalence of habitual snoring in adults was found to be 6.64%. According to the study, between 1.64% and 3.42% of Indians suffer with sleep disordered breathing. A vital component of human functioning is sleep. Numerous health issues arise from sleep difficulties since they lower the quality of life. In India, the prevalence of sleep problems is very high. Insomnia, obstructive sleep apnea, hypersomnia, restless legs syndrome, and shift work disorder are among the common sleep disorders. To the best of the authors' knowledge, no empirical study has examined insomnia and treatment-seeking among Indian older persons (60+) using a nationally representative sample. In light of this, this study evaluates the prevalence, determinants, and treatment-seeking behavior of insomnia in older Indian adults. These issues can be resolved by applying problem-solving techniques, which have also been shown in a recent study to be effective in treating insomnia in India. Working with the Indian population may therefore need us to incorporate problem-solving techniques into CBT-I. Between 51 and 58% of respondents said they regularly slept past 11 p.m. throughout the previous three years. Due to growing concerns about sleep issues, one in three Indians believes they suffer from insomnia. Over the years, 84–90% of respondents have continued to use their phones before bed, and nearly half of them have reported feeling exhausted in the morning.[20-24]



Fig. 3: The rate of Insomnia.

ETIOLOGY

Insomnia can also result from stressful life events like divorce, losing a job, or a loved one passing away or becoming unwell. schedule for work or travel. Circadian rhythms, sometimes referred to as your body's "internal clock," regulate your body's temperature, metabolism, and sleep-wake cycle. If these cycles are disturbed, sleeplessness may result. Comorbid medical and mental health disorders, older age, and female gender are among the risk factors linked to a higher prevalence of chronic insomnia. About 40% of persons who suffer from insomnia also have a diagnosable mental illness, most commonly depression. Perhaps the only sleep illness for which there has been a significant degree of top-down theorisation is insomnia. This might be the case because understanding an illness with several underlying causes and a gradual progression requires a framework. Four broad theories about the pathophysiology and aetiology of insomnia are compiled and assessed extensively. We specifically go over how each model describes the hyperarousal that is assumed to be the cause of disrupted sleep.[25-29] More details about how circadian factors and sleep homeostasis might mediate, modulate, or interact with hyperarousal are given. According to this psychobiologic inhibition model, issues with sleep initiation or maintenance may arise in the early stages of chronic insomnia due to malfunctions in the neurobiologic processes that typically prevent awake and allow sleep. Although chronic insomnia might be primary or secondary, its effects are the same, making it a distinct clinical disease. Although the significance of psychological and circadian factors, as well as the role of stress reactivity and hyperarousal, in causing sleep disorders, is well understood, it is still unknown how these factors interact to cause chronic insomnia. Hyperarousal could be an independent variable, a secondary impact, or a causative component. Emotional, cognitive, and personality components are examples of psychological elements. The dearth of knowledge on the interaction of neurological, endocrine, and hereditary variables limits our understanding of chronic insomnia.[30-33] A frequent sleep issue that can make it difficult to fall or remain asleep is insomnia. Additionally, you can wake up too early and find it difficult to fall back asleep. When you wake up, you can still feel exhausted. Your attitude and energy levels can be negatively impacted by insomnia. Additionally, it may have an impact on your well-being, productivity, and standard of living.[34]

PATHOPHYSIOLOGY

Chronic unhappiness with the amount or quality of sleep, which is linked to difficulty falling asleep, difficulty getting back to sleep at night, and/or waking up earlier than desired in the

morning, are the hallmark of insomnia disorder. There is still no widely recognised model for the nature, aetiology, and pathophysiology of insomnia, despite advances in our knowledge. Gaining more knowledge about the pathophysiology of insomnia could help identify potential preventative and treatment targets as well as crucial details about how and under what circumstances the problem arises and persists. Dissatisfaction with the amount or quality of sleep, difficulty falling asleep, difficulty going back to sleep at night, and/or waking up earlier than intended are the hallmarks of insomnia disorder. Significant distress or functional impairment, as well as daytime symptoms like exhaustion, excessive daytime drowsiness, mood swings, and cognitive impairment, are further characteristics of the illness. Sleep difficulties despite having enough opportunities to sleep distinguish insomnia from sleep deprivation.

According to varying prevalence estimates, between 30% and 43% of people report having at least one insomnia symptom at night. According to the majority of reports, 5% to 15% of people have an insomnia condition. 4, 5, 7, and 8. Between 31% and 75% of patients have chronic insomnia, with over two-thirds of those patients reporting symptoms for at least a year.[35-38] Chronic insomnia is predisposed to by both genetic and epigenetic factors. The involvement of several genes is demonstrated by genome-wide association studies. Psychiatric disorders, sleeplessness, restless legs syndrome, and cardiometabolic characteristics are all influenced by shared hereditary variables. The brain cell types that express genes related to insomnia belong to the circuits that regulate emotions rather than sleep. A switch mechanism between neuronal cell groups that promote sleep and those that promote wakefulness is proposed by the flip-flop switch model of sleep regulation. Cells in the hypothalamus that trigger the brainstem's reticular formation control wakefulness. The neurotransmitters galanin and gamma-aminobutyric acid (GABA) block the wake-promoting centres while the sleep-inducing centres are activated in the ventrolateral preoptic nucleus. In contrast, the neurotransmitters serotonin and noradrenaline suppress the ventrolateral preoptic nucleus. An imbalance between the systems that induce sleep and arousal may lead to chronic insomnia. Although studies have not demonstrated that circadian rhythms and homeostatic sleep mechanisms (sleep drive) are the main causes of chronic insomnia, they are involved in this switch process. Emotion is a third factor that contributes to sleeplessness. An important risk factor for disturbed sleep is stressful situations. The risk genes for insomnia are impacted by early, unfavourable childhood experiences. Chronic insomnia is a complex, polygenic stress-related illness that is most likely brought on by a combination of environmental and

genetic factors acting in concert within an epigenetic framework.[39-41]

EVALUATION OF INSOMNIA

Three primary criteria must be met in order to diagnose insomnia disorder: consistent difficulties sleeping, sufficient chance for sleep, and related dysfunction during the day. This review covers the symptoms, diagnosis, and differential diagnosis of insomnia. There is a distinct discussion of the causes, effects, and management of insomnia. Three primary criteria must be met in order to diagnose insomnia disorder: consistent difficulties sleeping, sufficient chance for sleep, and related dysfunction during the day. As more is discovered about insomnia, the criteria for diagnosing this sleep condition are always changing. Current criteria for diagnosing insomnia require that patients report at least one of the following issues. Having trouble falling asleep, having trouble staying asleep at night, frequently waking up sooner than preferred, and sentiments of aversion to sleeping at a decent hour. difficulty falling asleep without parental or caretaker's assistance. The time of insomnia, the patient's sleep patterns (also known as sleep hygiene), and whether the patient is exhibiting signs of sleep disorders linked to insomnia are all important considerations for the sleep history. If you have symptoms like two or more of the statements in the Sleep Disorders Screening Survey, you may have insomnia, according to the Insomnia Severity Index. If you answer "yes" to any of these questions, you might be experiencing signs of a sleep problem. We strongly suggest that you speak with your healthcare physician about these sleep issues. A person's medical, mental, and drug use histories are taken into consideration while diagnosing chronic insomnia. Although they are not usually advised for the first assessment, laboratory or imaging tests might be taken into account if there are suspicions of underlying medical comorbidities. A complete blood count, thyroid studies, liver and renal function, C-reactive protein, ferritin, and vitamin B12 are examples of laboratory tests that may be performed if necessary. Other studies may include brain imaging, electrocardiograms, electroencephalograms, or circadian markers like melatonin and core body temperature. According to guidelines, a sleep diary should be kept for seven to fourteen days. A dependable and affordable method of evaluating a person's sleep-wake cycle is through sleep logs or diaries. Sleep logs also include documentation of alcohol and caffeine consumption, bedtime activities, and daytime napping.[42] Total sleep duration, wakefulness following sleep onset, sleep efficiency, and disruptions to the circadian rhythm are all measured using sleep logs. Determining the quality and dependability of the diary data is the main drawback of the sleep log. To determine how severe insomnia is, validated scales like the ISI or the Sleep

Condition Indicator might be utilised. The Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale are two additional often-used used validated measures. When there is a suspicion of sleep-related movement problems like restless legs syndrome or breathing disorders like obstructive sleep apnea, polysomnography is advised. However, unless a co-occurring sleep disturbance is detected, it is not recommended in the first evaluation of primary insomnia. A non-invasive tool for recording gross motor activity while awake and asleep is a wrist actigraph. Actigraphy evaluates a number of sleep metrics, such as the length of total sleep, awake time following sleep onset, sleep latency, and naps during the day. Actigraphy's incapacity to identify irregular breathing patterns or periodic limb motions, however, is a significant drawback. When abnormalities of the circadian sleep-wake rhythm are detected, actigraphy is advised.[43,44]

INSOMNIA TREATMENT AND MANAGEMENT

Nonpharmacological Handling. Because it works well for both daytime and nocturnal symptoms as well as concomitant problems, international recommendations consistently suggest cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia. CBT-I is a manualized treatment that involves behavioural and cognitive restructuring and is usually administered by a qualified therapist to a group or person. The three-factor model of chronic insomnia—predisposing, precipitating, and sustaining factors—is the foundation of CBT-I. Many people can get peaceful sleep by altering their sleeping patterns and addressing any insomnia-related problems, such as stress, illnesses, or medications. Your doctor might suggest cognitive behavioural therapy (CBT), medication, or both to help you relax and sleep better if these measures don't work. Therapy using stimulus control. By using this technique, you may teach your body and mind to sleep more easily and not to resist it. For instance, you may be encouraged to use the bed exclusively for sleep and sex and to establish a regular time for going to bed and waking up rather than napping. If you can't fall asleep in 20 minutes, you might also be instructed to leave the bedroom and come back only when you're tired. Techniques for relaxation: Breathing techniques, biofeedback, and progressive muscle relaxation can all help reduce anxiety before bed. By using these techniques, you can relax by managing your heart rate, breathing, and tense muscles. Sleep restriction: Using this technique, you obtain less sleep by cutting down on the amount of time you spend in bed and ceasing to take naps during the day. You are more exhausted the following evening as a result. You gradually extend the amount of time you spend in bed once your sleep quality improves. Remaining passively awake: Also known as paradoxical

intention, this acquired insomnia technique attempts to lessen your anxiety and concern about falling asleep. Instead of expecting to fall asleep, you climb into bed and make an effort to stay awake. This method makes it easier to fall asleep by lowering your excessive concentration on sleep and concern about not sleeping. Light therapy: You can use light to slow down your internal clock if you go to bed too early and wake up too early. In the nights, you can utilize a light box or go outside when it's light outside. Consult your physician for guidance.[45] There is moderate-to-low quality evidence supporting pharmacological guidelines for the pharmacologic treatment of chronic insomnia in adults, according to the 2017 American Academy of Sleep Medicine Clinical Practice Guideline. Nonetheless, it offers the following dosage guidelines: Eszopiclone 2 or 3 mg before bed; ramelteon 8 mg before bed; temazepam 15 mg before bed; triazolam 0.25 mg before bed; zaleplon 5 or 10 mg before bed; or zolpidem 10 mg before bed are medications used to treat sleep-onset insomnia. Doxepin 3 or 6 mg before bed; eszopiclone 2 or 3 mg before bed; temazepam 15 mg before bed; suvorexant 10, 15, or 20 mg before bed; or zolpidem 10 mg before bed are medications used to treat sleep maintenance insomnia. An update on the diagnosis and management of insomnia is provided by the European Insomnia Guidelines. The following pharmaceutical approaches are suggested by 2023 for the treatment of persistent insomnia, with a consideration of the benefits and drawbacks for each patient: Short-term (less than four weeks) insomnia can be treated with benzodiazepines and benzodiazepine receptor agonists; the patient should be informed of the benefits and drawbacks of longer-term medication. After taking into account the contraindications, sedating antidepressants at low dosages can be used to treat insomnia temporarily; the patient should be informed of the benefits and drawbacks of longer-term medication.

For a maximum of three months, orexin receptor antagonists can be used to treat insomnia; the patient should be informed of the benefits and drawbacks of longer-term medication. Management of Pharmacology Classes of medications: Agonists for the gamma-aminobutyric acid-A receptor: Benzodiazepines and benzodiazepine receptor agonists have sedative, anxiolytic, muscle relaxant, and hypnotic actions by binding to GABA subtype A receptors (GABAARs). The receptor affinity for distinct GABAAR subtypes is a notable distinction between the two groups. The affinities of benzodiazepine receptor agonists for distinct alpha subunit subtypes vary, despite the fact that all benzodiazepines have a similar affinity for diverse subtypes of alpha subunits. For instance, eszopiclone has a greater affinity for the alpha-2 and alpha-3 subunits of the GABA receptor than do zolpidem and zaleplon, which

have a lower affinity for the alpha-1 subunit and a higher affinity for the alpha-2 and alpha-3 subunits. Benzodiazepines and benzodiazepine receptor agonists have a variety of half-lives and are effective at initiating and maintaining sleep. Cognitive and motor impairment, sedation the following day, anterograde amnesia, rebound insomnia, nausea, headaches, complicated sleep-related behaviour, and long-term risks like dependence, depression, falls, hip fractures, and dementia are some potential drawbacks of benzodiazepines and benzodiazepine receptor agonists. For people over 65, the Beers Criteria advise against using benzodiazepines and benzodiazepine receptor agonists.[46] The FDA has authorized four benzodiazepines—temazepam, triazolam, flurazepam, and estazolam—for the treatment of insomnia. The FDA has approved extended release and sublingual versions of zolpidem, zaleplon, and eszopiclone as benzodiazepine receptor agonists for the treatment of insomnia. Antagonists of Dual Orexin Receptors: To counteract orexin/hypocretin-mediated nighttime awakening, suvorexant, lemborexant, and daridorexant prevent wake-promoting orexins A and B from binding to OX1 and OX2 receptors. Because of safety concerns regarding the increased risk of driving difficulties the following day, increased somnolence throughout the day, and narcolepsy-like symptoms such hypnogogic-hypnopompic hallucinations, cataplexy, and vivid dreams, the FDA does not suggest larger doses of these drugs. Due to potential underlying mechanisms of orexin antagonism, these medicines are contraindicated in narcoleptic patients. Drugs that block melatonin receptors and melatonin: The pineal gland naturally produces the hormone melatonin. The hypothalamus and suprachiasmatic nucleus' circadian systems control this hormone's levels. The FDA has approved melatonin for the treatment of insomnia, particularly in older persons, and it is accessible over-the-counter. Melatonin absorption may be slowed down by food. By having a greater affinity than melatonin for the MT1 and MT2 receptors in the suprachiasmatic nucleus, ramelteon reduces sleep latency. Tasimelteon is a melatonin receptor agonist that helps people with non-24-hour sleep-wake disorders and Smith-Magenis syndrome initiate and maintain their sleep. Fatigue, dizziness, and somnolence are possible drawbacks. Antidepressants: Medications that block the histamine-1 receptor Low dosages of the tricyclic antidepressant doxepin can effectively treat insomnia related to sleep maintenance, including increases in overall sleep duration, alertness following sleep start, and sleep efficiency. Doxepin functions as a pure histamine-1 receptor antagonist at low dosages. Doxepin exhibits antihistaminic, antiserotonergic, anticholinergic, and antiadrenergic effects at large dosages. When taken in small amounts, doxepin might cause headaches and drowsiness. Because of their antihistaminic properties, trazodone, mirtazapine, amitriptyline, and nortriptyline are the most often prescribed

antidepressants for treating insomnia. Anticonvulsant drugs: Gabapentin may reduce waking time after sleep onset and increase sleep efficiency. Additionally, this drug may help individuals who suffer from alcoholism sleep better. In patients with fibromyalgia or generalised anxiety disorder, pregabalin may lessen insomnia. Sedating antihistamines: Central histamine receptor antagonists such as hydroxyzine and diphenhydramine are sold over-the-counter. Anticholinergic side effects such dry mouth, constipation, and cognitive impairment are drawbacks. The efficacy of antihistaminergic medications in treating insomnia is not well supported by research. The Indian Psychiatric Society has made the decision to revise the current recommendations in light of new research and developments in the treatment of sleep disorders. However, when you think about these standards for your practice, a few things need to be kept in mind: There is a dearth of original Indian research in this field. With the use of current evidence-based insomnia practice parameters when available and consensus-based recommendations to fill in the gaps in areas where such parameters are lacking, this clinical guideline aims to give clinicians a useful framework for the assessment and disease management of chronic adult insomnia. The Clinical Practice Guidelines (CPG) for the treatment of sleep disorders were initially published by the Indian Psychiatric Society (IPS) in 2006 and were later updated in 2017.Taking a history and performing a general physical examination are the first steps in managing an insomnia problem. It is crucial since insomnia can be mistaken for a variety of other sleep disorders. Therefore, being aware of these mimics will aid the doctor in making a precise diagnosis. Standard) For the treatment of chronic insomnia, multicomponent therapy—without cognitive therapy—is a recommended and successful treatment. (Guideline) Biofeedback therapy, paradoxical intention, and sleep restriction are further popular treatments. The first step in treating comorbid insomnias is to treat the comorbid disorder. This could involve dopaminergic therapy for movement disorders, the removal of stimulating medicines, the best possible management of pain or other illnesses, or the treatment of major depressive disorder.[47-56]

DISCUSSION AND CONCLUSION

Our review papers provide an overview of insomnia and discuss its pathophysiology, epidemiology, diagnostics, alternative therapeutics, and several causes. According to our findings, more clinical research is necessary because of the complexity of insomnia, even though it can be treated with neurological medications and other therapies. More randomised controlled trials are required to treat insomnia. In the future, we plan to provide a first

insomnia assessment. Future counselling-based research in our state or country will assess patients' physical and mental health to provide more precise information about insomnia and its treatment, with the assistance of our colleagues.

ETHICAL STATEMENT

A pharmacist must behave honourably and truthfully. A pharmacist avoids behaviours that compromise their commitment to acting in the best interests of their patients, such as discriminatory actions, incorrect behaviour, and adverse working conditions that impair judgment. A pharmacist maintains their level of proficiency.

ACKNOWLEDGEMENT

The authors would like to thank Shri Venkateshwara University, Gajraula, Uttar Pradesh, India, City Women's College, Jankipuram, Lucknow, Uttar Pradesh, India, Goel Institute of Pharmacy & Sciences, Lucknow, U.P., India & Signa College of Pharmacy, Kanpur, Uttar Pradesh, India, for extending their facilities.

CONFLICT OF INTEREST

The authors attest that they are free of any known financial or personal conflicts of interest that would taint the findings of this study.

INFORMED CONSENT

Using websites, review articles, and other sources to produce research content.

REFERENCES

1. Perlis M, Jungquist C, Smith MT, Posner D: The Cognitive Behavioral Treatment of Insomnia: A Treatment Manual. Contract pending, 2003.
2. McCrae CS, Lichstein KL: Secondary insomnia: Diagnostic challenges and intervention opportunities. Sleep Med. Rev., 2001; 5: 47-61.
3. Monroe LJ: Psychological and physiological differences between good and poor sleepers. J Abnorm Psychol., 1967; 72: 255-264.
4. Haynes SN, Follingstad DR, McGowan WT: Insomnia: Sleep patterns and anxiety level. J Psychosom. Res., 1974; 18: 69-74.
5. Freedman RR, Sattler HL: Physiological and psychological factors in sleep-onset insomnia. J Abnorm Psychol., 1982; 91: 380-389.
6. Adam K, Tomeny M, Oswald I: Physiological and psychological differences between

good and poor sleepers. J Psychiatr. Res., 1986; 20: 301-316.

7. Stepanski E, Glinn M, Zorick F, et al: Heart rate changes in chronic insomnia. Stress Med., 1994; 10: 261-266.
8. Haynes SN, Adams A, Franzen M: The effects of pre-sleep stress on sleep-onset insomnia. J Abnorm Psychol., 1981; 90: 601-606.
9. Bonnet MH, Arand DL: 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep, 1995; 18: 581-588.
10. Bonnet MH, Arand DL: Physiological activation in patients with sleep state misperception. Psychosom Med., 1997; 59: 533-540.
11. Bonnet MH, Arand DL: Heart rate variability in insomniacs and matched normal sleepers. Psychosom. Med., 1998; 60: 610-615.
12. Bonnet MH, Arand DL: Caffeine use as a model of acute and chronic insomnia. Sleep, 1992; 15: 526-536.
13. Johns MW: Relationship between sleep habits, adrenocortical activity and personality. Psychosom. Med., 1971; 33: 499-508.
14. Vgontzas AN, Tsigos C, Bixler EO, et al: Chronic insomnia and activity of the stress system: A preliminary study. J Psychosom. Res., 1998; 45: 21-31.
15. Vgontzas AN, Bixler EO, Lin HM, et al: Chronic insomnia is associated with nyctohemeral activation of the hypothalamicpituitary-adrenal axis: Clinical implications. J Clin Endocrinol Metab., 2001; 86: 3787-3794.
16. Riemann D, Klein T, Rodenbeck A, et al: Nocturnal cortisol and melatonin secretion in primary insomnia. Psychiatry Res., 2002; 113: 17-27.
17. Ford DE, Kamerow DB: Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? [see comments]. JAMA., 1989; 262: 1479-1484.
18. Dryman A, Eaton WW: Affective symptoms associated with the onset of major depression in the community: Findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr Scand., 1991; 84: 1-5.
19. Breslau N, Roth T, Rosenthal L, Andreski P: Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol. Psychiatry, 1996; 39: 411-418.
20. Riemann D., Spiegelhalder K., Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med. Rev., 2010; 14(1): 19-31.
21. Perlis ML, Giles DE, Mendelson WB, Bootzin RR, Wyatt JK. Psychophysiological

insomnia: the behavioural model and a neurocognitive perspective. J. Sleep Res., 1997; 6(3): 179-188.

22. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev., 2010; 14(1): 9-15.
23. Feige B, Baglioni C, Spiegelhalder K, Hirscher V, Nissen C, Riemann D. The microstructure of sleep in primary insomnia: an overview and extension. Int J Psychophysiol., 2013; 89(2): 171-180.
24. Espie CA. Insomnia: conceptual issues in the development, persistence, and treatment of sleep disorder in adults. Annu Rev Psychol., 2002; 53: 215-243.
25. Harvey AG. A cognitive model of insomnia. Behav Res. Ther., 2002; 40(8): 869-893.
26. Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practices of Sleep Medicine. St. Louis, MO., Elsevier, 2011.
27. Bonnet MH, Arand DL. 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep, 1995; 18(7): 581-588.
28. Partinen M, Kaprio J, Koskenvuo M, Putkonen P, Langinvainio H. Genetic and environmental determination of human sleep, 1983; 6(3): 179 - 185.
29. Kelly JM, Bianchi MT. Mammalian sleep genetics. Neurogenetics., 2012; 13(4): 287-326.
30. Seugnet L, Suzuki Y, Th imgan M, et al. Identifying sleep regulatory genes using a Drosophila model of insomnia. J Neurosci., 2009; 29(22): 7148-7157.
31. Gregory AM, Rijsdijk FV, Eley TC. A twin-study of sleep difficulties in school-aged children. Child Dev., 2006; 77(6): 1668-1679.
32. Drake CL, Friedman NP, Wright KP Jr, Roth T. Sleep reactivity and insomnia: genetic and environmental influences. Sleep, 2011; 34(9): 1179-1188.
33. Watson NF, Goldberg J, Arguelles L, Buchwald D. Genetic and environmental infl uences on insomnia, daytime sleepiness, and obesity in twins. Sleep, 2006; 29(5): 645-649.
34. Gehrman PR, Meltzer LJ, Moore M, et al. Heritability of insomnia symptoms in youth and their relationship to depression and anxiety. Sleep, 2011; 34(12): 1641-1646.
35. Wing YK, Zhang J, Lam SP, et al. Familial aggregation and heritability of insomnia in a community-based study. Sleep Med., 2012; 13(8): 985-990.
36. Wang CC, Lung FW. The role of PGC-1 and Apo ε 4 in insomnia. Psychiatr Genet. 2012; 22(2): 82-87.
37. Brower KJ, Wojnar M, Sliwerska E, Armitage R, Burmeister M. PER3 polymorphism

and insomnia severity in alcohol dependence. Sleep, 2012; 35(4): 571-577.

38. Zeitzer JM, Fisicaro RA, Grove ME, Mignot E, Yesavage JA, Friedman L. Faster REM sleep EEG and worse restedness in older insomniacs with HLA DQB1*0602. Psychiatry Res., 2011; 187(3): 397-400.
39. Serretti A, Benedetti F, Mandelli L, et al. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J. Med. Genet. B. Neuropsychiatr Genet., 2003; 121B(1): 35-38.
40. Deuschle M, Schredl M, Schilling C, et al. Association between a serotonin transporter length polymorphism and primary insomnia. Sleep, 2010; 33(3): 343-347.
41. Ban HJ, Kim SC, Seo J, Kang HB, Choi JK. Genetic and metabolic characterization of insomnia. PLoS. ONE, 2011; 6(4): e18455.
42. Clinton JM, Davis CJ, Zielinski MR, Jewett KA , Krueger JM . Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med., 2011; 7(suppl 5): S38-S42.
43. Kuisk LA, Bertelson AD, Walsh JK: Presleep cognitive hyperarousal and affect as factors in objective and subjective insomnia. Percept Mot. Skills, 1989; 69: 1219-1225.
44. Smith MT, Perlis ML, Smith MS, Giles DE: Pre-sleep cognitions in patients with insomnia secondary to chronic pain. J. Behav. Med., 2001; 24: 93-114.
45. Morin CM, Blais F, Savard J: Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav. Res. Ther., 2002; 40: 741-752.
46. Morin CM, Stone J, Trinkle D, et al: Dysfunctional beliefs and attitudes about sleep among older adults with and without insomnia complaints. Psychol Aging, 1993; 8: 463-467.
47. Edinger JD: Does cognitive-behavioral insomnia therapy alter dysfunctional beliefs about sleep? Sleep, 2001; 24: 599.
48. Harvey AG: A cognitive model of insomnia. Behav. Res. Ther., 2002; 40: 869-893.
49. Semler CN, Harvey AG: Monitoring of sleep-related threat: A pilot study of the sleep associated monitoring index (SAMI). Psychosom. Med., 2004; 66: 242-250.
50. Neitzert-Semler C, Harvey AG; An investigation of monitoring for sleep-related threat in primary insomnia. Behaviour Research and Therapy in press.
51. Harvey AG: Identifying safety behaviors in insomnia. J. Nerv. Ment. Dis., 2002; 190: 16-21.
52. Kleitman N: Sleep and Wakefulness. Chicago, University of Chicago Press, 1987.
53. Harvey AG: Sleep hygiene and sleep-onset insomnia. J Nerv. Ment. Dis., 2000; 188: 53-55.

54. Chesson AL Jr, Anderson WM, Littner M, et al: Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep, 1999; 22: 1128-1133.
55. Stepanski EJ, Wyatt JK: Use of sleep hygiene in the treatment of insomnia. Sleep Med. Rev., 2003; 7: 215-225.
56. Bootzin RR: Stimulus control treatment for insomnia. Programs and abstracts of the 80th Annual Convention of the American Psychological Association; Honolulu, Hawaii, September 2, 1972.